On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.